Fresno, California 2021-10-12 14:07:15 –
Pharmaceutical company Merck We requested an FDA emergency permit on Monday for a COVID-19 antiviral drug named molnupiravir.
“This drug looks very promising and is actually a reused drug,” said Dr. Nevan Krogan, director of the UCSF Institute for Quantitative Biological Sciences. “It was originally created to fight influenza, but it actually targets influenza proteins that are similar to the SARS-CoV-2 protein.”
According to a pharmaceutical study of 775 patients, antiviral drugs reduce hospitalization and mortality in patients with early COVID-19 symptoms by 50%.
Patients should take it within the first few days of exposure.
Deepak Srivastava, President of the Gladstone Institutes, said:
Dr. Deepak Srivastava, director of the Gladstone Institutes, and Dr. Nevan Krogan, director of the Quantitative Biosciences Institute at UCSF, have a team of scientists studying results that are stronger than 50% protection.
“In the future, we’ll need a cocktail that takes a couple of medicines at a time. It was a breakthrough for HIV with multiple medicines in a cocktail,” said Dr. Crogan. ..
In both laboratories, scientists mix drugs previously approved for other illnesses. Both experts agree that this pill is not a substitute for the vaccine.
“Vaccination reduces the risk of hospitalization and death by 95%,” said Dr. Srivastava. This pill does it only at a 50% rate. So you are tossing a coin. “
The FDA is responsible for investigating Merck’s data. If approved, the decision may be made within a few weeks.
According to Dr. Srivastava, there is one concern that the FDA will closely track.
“There are similar tablets that are known to cause mutations in our DNA. Merck studied it with their drug, and although it doesn’t look like they saw that signal, This is what the FDA is considering. ”
Copyright © 2021 KGO-TV. all rights reserved.
New Merck COVID-19 pill is not a substitute for the vaccine, according to experts — here’s why Source link New Merck COVID-19 pill is not a substitute for the vaccine, according to experts — here’s why